Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in computational target discovery, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat during the virtual conference on February 11, 2025, at 8am ET.
Investors and interested parties can access a live webcast of the presentation through the Investor Relations section of Compugen's website at www.cgen.com. For those unable to attend the live session, a replay will be made available after the event.
Compugen (NASDAQ: CGEN), un'azienda di immunoterapia oncologica in fase clinica specializzata nella scoperta computazionale dei target, ha annunciato la sua prossima partecipazione alla 35ª Conferenza Annuale sulle Scienze della Vita Oppenheimer. Il management dell'azienda parteciperà a una chiacchierata informale durante la conferenza virtuale il 11 febbraio 2025, alle 8:00 ET.
Investitori e parti interessate possono accedere a una diretta streaming della presentazione attraverso la sezione Relazioni con gli Investitori del sito web di Compugen all'indirizzo www.cgen.com. Per chi non potesse assistere alla sessione dal vivo, sarà disponibile una registrazione dopo l'evento.
Compugen (NASDAQ: CGEN), una compañía de inmunoterapia contra el cáncer en etapa clínica especializada en el descubrimiento de objetivos computacionales, ha anunciado su próxima participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. La dirección de la compañía participará en una charla informal durante la conferencia virtual el 11 de febrero de 2025, a las 8 a.m. ET.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Relaciones con Inversores en el sitio web de Compugen en www.cgen.com. Para quienes no puedan asistir a la sesión en vivo, se realizará una reproducción disponible después del evento.
Compugen (NASDAQ: CGEN), 임상 단계의 암 면역 요법 회사로 계산적 타겟 발견에 전문화되어 있으며 오펜하이머 제35회 연례 헬스케어 생명과학 콘퍼런스에 참여할 것이라고 발표했습니다. 회사의 경영진은 2025년 2월 11일, 동부표준시 기준 오전 8시에 가상의 콘퍼런스에서 화기애애한 대화에 참여할 예정입니다.
투자자와 관심 있는 분들은 Compugen 웹사이트의 투자자 관계 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 라이브 세션에 참석할 수 없는 분들을 위해 이벤트 후 재생 가능한 녹화본이 제공될 예정입니다.
Compugen (NASDAQ: CGEN), une entreprise d'immunothérapie anti-cancer en phase clinique spécialisée dans la découverte de cibles computationnelles, a annoncé sa prochaine participation à la 35e Conférence Annuelle Oppenheimer sur la Santé et les Sciences de la Vie. La direction de l'entreprise participera à une discussion informelle lors de la conférence virtuelle le 11 février 2025 à 8h ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Relations Investisseurs du site web de Compugen à l'adresse www.cgen.com. Pour ceux qui ne peuvent pas assister à la session en direct, un replay sera disponible après l'événement.
Compugen (NASDAQ: CGEN), ein Unternehmen für Immuntherapie gegen Krebs in der klinischen Phase, das sich auf die rechnergestützte Zielentdeckung spezialisiert hat, hat seine bevorstehende Teilnahme an der 35. Jahreskonferenz für Gesundheits- und Lebenswissenschaften von Oppenheimer angekündigt. Das Management des Unternehmens wird am 11. Februar 2025 um 8 Uhr ET an einem informellen Gespräch während der virtuellen Konferenz teilnehmen.
Investoren und Interessierte können die Live-Übertragung der Präsentation über den Bereich Investor Relations auf der Website von Compugen unter www.cgen.com abrufen. Für diejenigen, die an der Live-Sitzung nicht teilnehmen können, wird nach der Veranstaltung ein Replay zur Verfügung stehen.
- None.
- None.
HOLON,
A live webcast of the fireside chat will be available on the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302367189.html
SOURCE Compugen Ltd.
FAQ
When is Compugen (CGEN) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Compugen's (CGEN) Oppenheimer Conference presentation?
What type of presentation will Compugen (CGEN) give at the 2025 Oppenheimer Conference?
Is the Oppenheimer Healthcare Conference 2025 where CGEN is presenting in-person or virtual?
